Trazimera

Introducing TRAZIMERA
Building onto the clinical experience of trastuzumab
*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar and the reference product.
Terms and Conditions
By using this program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions below:
  • The Pfizer Oncology Together Co-Pay Savings Program for Injectables for TRAZIMERA is not valid for patients who are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
  • Program offer is not valid for cash-paying patients.
  • With this program, eligible patients may pay as little as $0 co-pay per TRAZIMERA treatment, subject to a maximum benefit of $25,000 per calendar year for out-of-pocket expenses for TRAZIMERA including co-pays or coinsurances.
  • The amount of any benefit is the difference between your co-pay and $0.
  • After the maximum of $25,000, you will be responsible for the remaining monthly out-of-pocket costs.
  • Patient must have private insurance with coverage of TRAZIMERA.
  • This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plans or other private health or pharmacy benefit programs.
  • You must deduct the value of this assistance from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
  • You are responsible for reporting use of the program to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the program, as may be required.
  • You should not use the program if your insurer or health plan prohibits use of manufacturer co-pay assistance programs.
  • This program is not valid where prohibited by law.
  • This program cannot be combined with any other savings, free trial or similar offer for the specified prescription.
  • This program is not health insurance.
  • This program is good only in the U.S. and Puerto Rico.
  • This program is limited to 1 per person during this offering period and is not transferable.
  • No other purchase is necessary.
  • Data related to your redemption of the program assistance may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other assistance redemptions and will not identify you.
  • Pfizer reserves the right to rescind, revoke or amend this program without notice.
  • This program may not be available to patients in all states.
  • For more information about Pfizer, visit www.pfizer.com.
  • For more information about the Pfizer Oncology Together Co-Pay Savings Program for Injectables, call 1-877-744-5675, or write to
    Pfizer Oncology Together Co-Pay Savings Program for Injectables
    P.O. Box 220366
    Charlotte, NC 28222
  • Program terms will expire at the end of each calendar year. Before the calendar year ends, you will receive information and eligibility requirements for continued participation.
For patients to be eligible for the Injectables Co-Pay Program for TRAZIMERA, they must have commercial insurance that covers TRAZIMERA and they cannot be enrolled in a state or federally funded insurance program. Whether a co-pay expense is eligible for the Injectables Co-Pay Program for TRAZIMERA benefit, will be determined at the time the benefit is paid. Co-pay expenses must be in connection with a separately paid claim for TRAZIMERA administered in the outpatient setting.
§The Injectables Co-Pay Program for TRAZIMERA will pay the co-pay for TRAZIMERA up to the annual assistance limit of $25,000 per calendar year per patient.
||The Injectables Co-Pay Program for TRAZIMERA provides assistance for eligible, commercially insured patients prescribed TRAZIMERA for co-pays or coinsurance incurred for TRAZIMERA up to $25,000 per calendar year. It does not cover or provide support for supplies, services, procedures, or any other physician-related services associated with TRAZIMERA treatment.
 
References:
1. TRAZIMERA [prescribing information]. New York, NY: Pfizer Inc.; March 2019.
2. IMS Institute for Healthcare Informatics. Delivering on the Potential of Biosimilar Medicines: The Role of Functioning Competitive Markets. Parsippany, NJ: IMS; March 2016.